Comparable stake leader
TORONTO DOMINION BANK
SEC ownership of UroGen Pharma Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001668243.
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
50/50
Latest evidence
22 Jun 2026
- Public ticker
- URGN on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TORONTO DOMINION BANK
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
TORONTO DOMINION BANK
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
22 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001668243
- Issuer location
- Ra'anana, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of UroGen Pharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TORONTO DOMINION BANK
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
50/50
Latest evidence
22 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 5.4%
13D/G row: TORONTO DOMINION BANK
Showing 1-8 of 50 holder rows.
Quick read
TORONTO DOMINION BANK leads the comparable SEC ownership view at 5.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TORONTO DOMINION BANK's linked filing trail.
Comparable ownership
Top 5
TORONTO DOMINION BANK
5.4%
MORGAN STANLEY
5.4%
BlackRock, Inc.
5.2%
MENORA MIVTACHIM HOLDINGS LTD.
5%
Soleus Capital Master Fund, L.P.
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TORONTO DOMINION BANK |
13D/G
13F
The Toronto-Dominion Bank · Company
|
5.4%
|
$53,066,960
2,616,714 shares
|
+$6,375,626 | 31 Mar 2026 |
| MORGAN STANLEY |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$46,029,492
2,560,038 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.2%
from 13D/G
|
$51,163,295
2,845,567 shares
|
— | 31 Mar 2026 |
| MENORA MIVTACHIM HOLDINGS LTD. |
13D/G
13F
Company
|
5%
|
$24,780,614
2,303,031 shares
|
$0 | 11 Mar 2025 |
| Soleus Capital Master Fund, L.P. |
13D/G
|
4.7%
|
$31,114,400
2,185,000 shares
|
-$1,993,600 | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
3.5%
|
$34,556,086
1,703,949 shares
|
-$50,946,098 | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
2.8%
|
$13,740,520
1,277,000 shares
|
-$17,765,685 | 31 Mar 2025 |
| Monograph Capital Holdings Advisors, LLC |
13D/G
Monograph Capital Partners I, L.P.
|
1.8%
|
$8,503,556
838,615 shares
|
$0 | 05 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,837,332.
Buys
$0
Insiders: 0
Sells
$1,837,332
Insiders: 3
Net
-$1,837,332
Shares: -77,339
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 77,339
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 25,222 | $0 | $792,661 | -$792,661 |
| 3-6 | 0 | 14,852 | $0 | $292,436 | -$292,436 |
| 6-9 | 0 | 12,203 | $0 | $287,121 | -$287,121 |
| 9-12 | 0 | 25,062 | $0 | $465,115 | -$465,115 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to UroGen Pharma Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Ran Nussbaum
Net 12M change
-$1,837,333
Latest report
22 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ran Nussbaum | Director | $26,747,876 | Mixed | 21 Oct 2022 | ||
| Mark Schoenberg | Chief Medical Officer | $4,543,002 | -$1,479,932 | -25% | Filing P/S | 22 Jun 2026 |
| Jason Drew Smith | General Counsel | $1,094,527 | -$320,280 | -23% | Filing P/S | 31 Jan 2026 |
| Dong Kim | Chief Financial Officer | $493,809 | Mixed | 09 Sep 2024 | ||
| James A. Robinson Jr. | Director | $107,880 | Median | 22 Jun 2026 | ||
| Molly Henderson | Chief Financial Officer | $94,516 | Mixed | 31 Jan 2022 | ||
| Daniel George Wildman | Director | $39,560 | Mixed | 22 Jun 2026 | ||
| Leana Wen | Director | $39,560 | Mixed | 22 Jun 2026 | ||
| Cynthia M. Butitta | Director | $39,560 | Mixed | 22 Jun 2026 | ||
| Stuart Holden | Director | $39,560 | Mixed | 22 Jun 2026 | ||
| Chris Degnan | Chief Financial Officer | $38,418 | -$37,121 | -49% | Filing P/S | 31 Jan 2026 |
| Kathryn E. Falberg | Director | Mixed | 07 Jun 2021 | |||
| Elizabeth A. Barrett | Chief Executive Officer | Mixed | 31 Jan 2026 | |||
| Fred E. Cohen | Director | Mixed | 06 Aug 2024 | |||
| Shawn Cline Tomasello | Director | Mixed | 07 Jun 2021 | |||
| Arie Belldegrun | Director | Mixed | 22 Jun 2026 |
Recent insider transactions for UroGen Pharma Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -7.15% | $350,100 | $35.01 | -10,000 | 129,763 | 22 Jun 2026 | Direct |
| Daniel George Wildman | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 22 Jun 2026 | Direct | |||
| Daniel George Wildman | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 22 Jun 2026 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 22 Jun 2026 | Direct | |||
| James A. Robinson Jr. | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 22 Jun 2026 | Direct | |||
| Stuart Holden | URGN | Stock Option (right ot buy) | Award | 20,000 | 20,000 | 22 Jun 2026 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 22 Jun 2026 | Direct | |||
| Cynthia M. Butitta | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 22 Jun 2026 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 22 Jun 2026 | Direct | |||
| Leana Wen | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 22 Jun 2026 | Direct | |||
| Arie Belldegrun | URGN | Stock Option (right ot buy) | Award | 20,000 | 20,000 | 22 Jun 2026 | Direct | |||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -3.6% | $142,561 | $27.30 | -5,222 | 139,763 | 08 Jun 2026 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 7.41% | 10,000 | 144,985 | 08 Jun 2026 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -100% | -10,000 | 0 | 08 Jun 2026 | Direct | ||
| James A. Robinson Jr. | URGN | ordinary shares | Options Exercise | 50% | 2,000 | 6,000 | 26 May 2026 | Direct | ||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Options Exercise | -50% | -2,000 | 2,000 | 26 May 2026 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.9% | $300,000 | $30.00 | -10,000 | 134,985 | 08 May 2026 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -12.7% | $147,262 | $19.69 | -7,479 | 51,326 | 03 Feb 2026 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -4.84% | $145,174 | $19.69 | -7,373 | 144,985 | 03 Feb 2026 | Direct |
| Elizabeth A. Barrett | URGN | Restricted Stock Units | Award | 153,195 | 153,195 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 35.8% | 15,500 | 58,805 | 31 Jan 2026 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -100% | -15,500 | 0 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 9.59% | 13,333 | 152,358 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Award | 20,000 | 20,000 | 31 Jan 2026 | Direct | |||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -100% | -13,333 | 0 | 31 Jan 2026 | Direct | ||
| Chris Degnan | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Stuart Holden | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Stuart Holden | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Cynthia M. Butitta | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| James A. Robinson Jr. | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Leana Wen | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Daniel George Wildman | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Daniel George Wildman | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.71% | $250,000 | $25.00 | -10,000 | 139,025 | 19 Nov 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Sale | -49.1% | $37,121 | $16.85 | -2,203 | 2,280 | 08 Oct 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Options Exercise | 4,483 | 4,483 | 08 Oct 2025 | Direct | |||
| Chris Degnan | URGN | Restricted Stock Units | Options Exercise | -33.3% | -4,483 | 8,967 | 08 Oct 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -0.58% | $16,645 | $19.11 | -871 | 149,025 | 08 Sep 2025 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -3.39% | $29,047 | $19.11 | -1,520 | 43,305 | 08 Sep 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 1.12% | 1,667 | 149,896 | 07 Sep 2025 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -50% | -1,667 | 1,667 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 8.03% | 3,333 | 44,825 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -50% | -3,333 | 3,334 | 07 Sep 2025 | Direct | ||
| Daniel George Wildman | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Daniel George Wildman | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.